Rationale Schizophrenia-like cognitive deficits induced by phencyclidine (PCP), a drug commonly used to model schizophrenia in experimental animals, are attenuated by nitric oxide (NO) synthase inhibitors. Furthermore, PCP increases NO levels and sGC/cGMP signalling in the prefrontal cortex in rodents. Hence, a cortical NO/sGC/ cGMP signalling pathway may constitute a target for novel pharmacological therapies in schizophrenia. Objectives The objective of this study was to further investigate the role of NO signalling for a PCP-induced deficit in pre-attentive information processing. Materials and methods Male Sprague-Dawley rats were surgically implanted with NO-selective amperometric microsensors aimed at the prefrontal cortex, ventral hippocampus or nucleus accumbens, and NO levels and prepulse inhibition (PPI) were simultaneously assessed. Results PCP treatment increased NO levels in the prefrontal cortex and ventral hippocampus, but not in the nucleus accumbens. The increase in NO levels was not temporally correlated to the deficit in PPI induced by PCP. Furthermore, pretreatment with the neuronal NO synthase inhibitor Npropyl-L-arginine dose-dependently attenuated both the increase in prefrontal cortex NO levels and the deficit in PPI.
Introduction
Aberrations in nitric oxide (NO) signalling have been associated with schizophrenia in both clinical studies and animal models of the disorder (Baba et al. 2004; Bernstein et al. 2001; Bird et al. 2001) . Furthermore, genetic studies support a role of polymorphisms in neuronal NO synthase (NOS) gene as a risk factor for schizophrenia (Reif et al. 2006; Wratten et al. 2009 ). In addition, a number of studies in rodents using phencyclidine (PCP), a drug commonly used to model schizophrenia in experimental animals, show a beneficial effect of NOS inhibitors on schizophreniarelated cognitive deficits (Johansson et al. 1997; Klamer et al. 2004d Klamer et al. , 2005b Wass et al. 2006 Wass et al. , 2009 . Such an effect has also been demonstrated using neuronal NOS-selective inhibitors, suggesting that the NO-dependent effects of PCP involve increased neuronal NO production (Klamer et al. 2004a; Wiley 1998) . A role for NO dysregulation is supported by recent findings showing increases in NO levels and NO-dependent increases in cGMP signalling in the prefrontal cortex following PCP administration in rodents (Fejgin et al. 2008) . Furthermore, blocking the production of cGMP in the prefrontal cortex prevented a PCP-induced deficit in pre-attentive information processing (Fejgin et al. 2008) . Taken together, these observations suggest that at least some of the schizophrenia-related behavioural effects of PCP are caused by the activation of the prefrontal cortex neuronal NOS and the subsequent activation of the cGMP signalling cascade. It should be noted that there are discordant reports demonstrating that the NO donor sodium nitroprusside can attenuate PCPinduced behavioural effects (Bujas-Bobanovic et al. 2000) . Thus, the relationship between NO and the schizophrenialike effects of PCP is still unclear. However, the prefrontal cortex NO/sGC/cGMP signalling pathway may constitute an interesting target for novel pharmacological therapies in schizophrenia and possibly play a role in the pathophysiology of the disorder. In support of this, the NOS and sGC inhibitor methylene blue has been shown to have some effect as an adjuvant treatment in schizophrenia patients (Deutsch et al. 1997) and to attenuate the effects of PCP in rodents (Klamer et al. 2004b) . Again, there are conflicting data as the phosphodiesterase inhibitor sildenafil failed to improve cognitive function in a placebo-controlled study despite beneficial effects in animal models (Goff et al. 2009) .
In previous studies, we have used separate experiments to study the biochemical and behavioural NO dependence of PCP in rodents. Thus, a direct causal link between the observed increases in prefrontal cortex NO signalling and schizophrenia-like behavioural effects remains to be shown. In the present study, the role of NO signalling in the behavioural and biochemical effects of PCP was further investigated using simultaneous electrochemical detection of NO levels and assessment of pre-attentive information processing using prepulse inhibition (PPI) following PCP administration. Prepulse inhibition of the acoustic startle reflex is a translational behavioural paradigm that is widely used to assess pre-attentive information processing in schizophrenia models. Deficits in PPI are present in schizophrenia patients and are also found in experimental animals following administration of non-competitive NMDA receptor antagonists Swerdlow et al. 2008) . In the first series of experiments, rats were systemically treated with PCP and tested for PPI with concomitant measurement in NO levels in the prefrontal cortex, ventral hippocampus and nucleus accumbens. These brain regions were chosen based on their suggested involvement in both the pathophysiology of schizophrenia and the modulation of the PPI response. In a second series of experiments, rats were systemically treated with the neuronal NOS-selective inhibitor N-propyl-L-arginine (LNPA) and PCP and tested for PPI with concomitant measurement of NO levels in the prefrontal cortex to further investigate the involvement of the neuronal NOS isoform in a PCP-induced deficit in PPI.
Materials and methods

Animals
Male Sprague-Dawley rats (Taconic, Denmark, 280-400 g) were used. All animals were housed, with a maximum of four per cage (55×35×20 cm), in a colony room under constant temperature (20±1°C) and humidity (50±5%). Food and water were available ad libitum. The daylight cycle was maintained artificially (lights on from 0600 to 1800 hours), and the experiments were conducted during the light phase. The animals were allowed to acclimatise for at least 1 week prior to surgery. All experimental procedures used in the present study were approved by the Ethics Committee for Animal Experiments, Goteborg.
Drugs
Phencyclidine hydrochloride (PCP, Sigma Chemicals, St. Louis, MO, USA) and LNPA (Tocris, Bristol, UK) were used in the present study. PCP and LNPA were dissolved in saline (0.9% NaCl) and injected subcutaneously (s.c.) in a volume of 2 ml/kg. The doses of PCP and LNPA used were based on previously published studies (Johansson et al. 1997; Klamer et al. 2001 Klamer et al. , 2004a .
Surgical procedure
The rats were anaesthetised with isoflurane, placed in a Kopf stereotaxic instrument and kept on a heating pad to prevent hypothermia. An incision was placed down the midline of the skull and the bone was exposed. Two holes for the anchor screws, two holes for the reference (8-T Ag wire, 200-μm bare diameter; Advent Research Materials, UK) and auxiliary (8-T Ag wire) electrodes and one hole for the working (sensor) electrode were drilled. Electrodes were then implanted following a previously described procedure (Lowry et al. 1997) . The coordinates used for the medial prefrontal cortex relative to bregma were as follows: anterior +3.2 mm, lateral to midline ±0.8 mm, and ventral −4.2 mm from the brain surface. Similarly, the coordinates for the ventral hippocampus were −5.2, ±5.4 and −6.0 mm and for the nucleus accumbens +1.85, ±1.3 and −6.8 mm. The electrodes were inserted into the brain and connected to a pedestal that was secured to the anchor screws with dental cement. During surgery, the rats were administered 2.0 ml of saline to reduce postoperative dehydration and an analgesic (carprofen) to reduce postoperative pain. The animals were allowed to recover for 2-3 days before commencing experiments. They were housed individually in standard plastic cages (35×20×16 cm).
Electrochemical detection of NO Brain NO levels were determined using a NO-selective amperometric microsensor. The microsensor is a Nafionmodified Pt disk electrode (patent no. S2007/00774, Blue Box Sensors Ltd., Dublin, Ireland). The sensor design has been validated for in vitro and in vivo NO sensitivity (Brown et al. 2005 (Brown et al. , 2009 ) and in vitro selectivity against ascorbic acid, uric acid and dopamine (Brown and Lowry 2003) . The NO oxidation current (electrode potential of +0.90 V against an Ag reference electrode) was detected using a low-noise potentiostat (Biostat II, Electrochemical and Medical Systems, UK) and converted using an A/D converter (PowerLab, ADInstruments, UK). The digital signal was then recorded using Chart software (v5, ADInstruments) running on a PC. Individual working (sensor) electrodes were tested for ascorbic acid interference and calibrated to ensure NO sensitivity in vitro prior to surgery.
Prepulse inhibition experiments
Apparatus
Acoustic startle was recorded by a MOPS 3 startle response recording system (Metod och Produkt Svenska AB, Sweden). The animals were placed in a circular cabinet (diameter, 40 cm; wall height, 24 cm). A plastic horizontal disk (diameter, 39.5 cm) attached on top of the moving coil transducer was used as floor in the arena. The rat movements caused a displacement of the disk, the acceleration of which was converted to an analogue signal by the transducer. This signal was sampled and digitised by a microcomputer that also controlled the delivery of acoustic stimuli. Startle amplitude was defined as the maximum signal amplitude occurring 8-30 ms after the startle-eliciting stimulus. The acoustic stimuli consisted of white noise, which was delivered by three highfrequency loudspeakers built into the ceiling of the cabinet.
PPI paradigm
Each test session started with a 10-min adaptation period containing only white background noise at 62 dB(A). Startle pulse was set to 105 dB(A) and prepulse intensity to 15 dB(A) above background. Duration of acoustic stimuli was set to 20 ms for both prepulses and startle pulses, and interstimulus interval was set to 40 ms. Following the adaptation period, the animals were subjected to a pseudo-randomised combination of three prepulse-alone trials, 15 pulse-alone trials and 15 prepulse+pulse trials. Trials were separated by 5-to 15-s intervals. The duration of the PPI test was approximately 4 min, and the test was repeated for a total of 12 times with 10-min background noise only intervals between each test. The total length of the test session was approximately 168 min.
Experimental design
Each rat was connected to the in vivo voltammetry equipment on the day before the experiment to allow the NO oxidation current to reach a stable baseline. Every animal was initially administered saline (2 ml/kg, s.c.) and placed in the circular arena. After 5 min, they were exposed to white background noise only for 180 min to allow the animals to acclimatise to the test procedure. After a 2-day washout period, two PPI test sessions were conducted. All animals received both treatment combinations in a balanced crossover design. Each test was separated by a 3-to 4-daylong washout period. In experiment 1, each rat received an injection of saline or PCP (2 mg/kg) and was then placed in the arena, and 5 min later, the PPI test was started. In experiment 2, rats were first pretreated with LNPA (5 or 10 mg/kg, s.c.) and 10 min later received a second injection of saline or PCP (2 mg/kg). The animal was then placed in the arena, and 5 min later, the PPI test was started.
Probe placement verification
After termination of the experiments, the rats were decapitated. The brains were removed and frozen at −80°C. Sensor placement was verified by sectioning the brains with an atlas of the rat brain for reference (Franklin and Paxinos 1998) . All sensors were verified to be positioned within the prelimbic or infralimbic part of the prefrontal cortex at 3.2±0.4 mm anterior of bregma, the shell or core part of the nucleus accumbens at 1.85±0.4 mm anterior of bregma or the CA1 or CA2 part of the hippocampus at 5.2±0.4 mm posterior of bregma.
Data and statistical analysis
The NO oxidation current over time (sampling rate 4/s) recorded in chart was used as data. The mean of the sampling period (approximately 5 min) immediately prior to drug treatment was used as a baseline. The mean current change from the baseline was calculated for each 4-min sampling period corresponding to a PPI test.
PPI was analysed by calculating the mean response amplitude for pulse-alone trials (P) for each rat and test. This measure was used in the statistical analysis to assess drug-induced changes in acoustic startle response. The mean response amplitude for prepulse-pulse trials (PP) was also calculated and used to express the percent prepulse inhibition according to the following formula:
Using this formula, a 0% value denotes no difference between pulse-alone and prepulse-pulse response amplitudes and consequently no PPI.
Differences in NO levels between treatments (saline or LNPA+saline and PCP or LNPA+PCP) were assessed using a two-way repeated measures ANOVA with sampling time as within-subjects factor and treatment as between-subjects factor. For the PPI data, a two-way repeated measures ANOVA with sampling time as within-subjects factor and treatment as between-subjects factor including all animals in experiment 1 was performed. This was followed by a twoway ANOVA of the mean of the first and last four PPI tests with treatment and brain region as between-subjects factors. Experiment 2 was analysed using a two-way ANOVA of the mean of the first and last four PPI tests with treatment and dose as between-subjects factors. Group differences were further evaluated using Bonferroni's post hoc test. Two-tailed levels of significance were used and p<0.05 was considered statistically significant.
Results
Prefrontal cortex NO levels PCP (2 mg/kg) administration
The ANOVA showed that systemic administration of PCP induced an increase in NO levels (effect of treatment, F (1,154)=6.91, p<0.05) that was time-dependent (treatment× time interaction, F(11,154)=6.69, p<0.001). The post hoc test indicated a significant effect of PCP on NO levels during the 108-min (p<0.05), 122-min (p<0.01), 136-min (p< 0.01), 154-min (p<0.001) and 164-min (p<0.01) sampling times (Fig. 1a) .
Ventral hippocampus NO levels and PPI following PCP (2 mg/kg) administration
The two-way ANOVA demonstrated a significant timedependent increase in NO levels following PCP-induced administration (treatment×time interaction, F(11,110)= 2.04, p<0.05; Fig. 1b) .
Nucleus accumbens NO levels and PPI following PCP (2 mg/kg) administration
The two-way ANOVA did not reveal any main effects for the time and treatment factors and no significant interaction effect (Fig. 1c) .
Prefrontal cortex, ventral hippocampus and nucleus accumbens PPI following PCP (2 mg/kg) administration
The analysis of the PPI for all animals in experiment 1 showed a significant decrease in PPI after PCP treatment (effect of treatment, F(1,418)=21.68, p<0.0001) that was time-dependent (treatment×time interaction, F(11,418)= Fig. 1 Mean change in prefrontal cortex (n=8) (a), ventral hippocampus (n=6) (b) and nucleus accumbens (n=6) (c) NO oxidation current as compared to baseline for each 4-min sampling period corresponding to a PPI test. All animals received the two treatments in a semi-randomised order with a 2-day washout period between the saline (open circles) and PCP (filled circles) condition. Data are expressed as mean ± SEM current change (pA). *p<0.05 following a Bonferroni post hoc test 4.12, p<0.0001). Furthermore, there was a main effect of time per se on PPI levels (effect of time, F(11,418)=12.86, p<0.0001). The Bonferroni post hoc test demonstrated a significant group difference during the 10-min (p<0.001), 24-min (p<0.001), 38-min (p<0.001), 52-min (p<0.001), 108-min (p<0.01) and 164-min (p<0.05) sampling times (Fig. 2) .
Furthermore, a two-way ANOVA of the mean PPI during the first four PPI tests showed a main effect of treatment (F(1,34)=36.52, p<0.0001), but no effect of brain region or any treatment×brain region interaction effect (Fig. 3a) . The Bonferroni post hoc test demonstrated a significant difference between saline and PCP treatment for all brain regions, prefrontal cortex (p<0.001), ventral hippocampus (p<0.05) and nucleus accumbens (p<0.01).
A similar analysis of the mean PPI during the last four PPI tests also showed a main effect of treatment (F(1,34)= 8.21, p<0.01), but no effect of brain region or any treatment×brain region interaction effect (Fig. 3b) . Furthermore, the Bonferroni post hoc test did not reveal any significant differences in PPI between saline and PCP treatment groups.
Prefrontal cortex NO levels following LNPA (5 mg/kg) and PCP (2 mg/kg) administration
The analysis indicated that systemic administration of PCP increased NO levels (effect of treatment, F(1,110)=6.14, p<0.05) in a time-dependent manner (treatment×time interaction, F(11,110)=3.12, p<0.01). The post hoc test indicated a significant effect of PCP on NO levels during the 122-min (p<0.05), 136-min (p<0.01) and 154-min (p< 0.05) sampling times (Fig. 4a) .
Prefrontal cortex NO levels following LNPA (10 mg/kg) and PCP (2 mg/kg) administration
The two-way ANOVA did not show any main effect of treatment or time×treatment interaction, indicating that LNPA pretreatment attenuated a PCP-induced increase in NO levels (Fig. 4b) . However, there was a main effect of time (effect of time, F(11,110)=3.43, p<0.01), suggesting that pretreatment with LNPA (10 mg/kg) decreased NO levels per se.
PPI levels following LNPA (5 or 10 mg/kg) and PCP (2 mg/kg) administration
The two-way ANOVA of the mean PPI during the first four PPI tests did not show any main effect of treatment, dose or any treatment×dose interaction effect (Fig. 5a) . Similarly, the analysis of the mean PPI during the last four PPI tests did not demonstrate any treatment, dose or any treatment× dose interaction effect (Fig. 5b) .
Acoustic startle response
A t test was used to compare the mean acoustic startle response between treatment groups within each experiment, and no significant effect of treatment was found in any experiment (Table 1) .
Discussion
The present study confirms a previously observed increase in NO levels in the prefrontal cortex of rats following systemic PCP administration ). In addition, this effect tended to be more pronounced in the prefrontal cortex as compared to the ventral hippocampus, whereas no elevation of NO levels was found in the nucleus accumbens. The fact that PCP did not elicit an NO release in the nucleus accumbens may be due to regional differences in the anatomy and regulation of the NO system in the brain (Steinbusch et al. 2000) . Furthermore, systemic administration of PCP affects a number of neurotransmitter systems in several brain regions. This includes elevations of dopamine and serotonin levels and turnover (Jentsch et al. 1997; Martin et al. 1998 ). These effects have been linked to the PPI Fig. 5 Mean change in PPI levels for the first (10-52 min) (a) and last (122-164 min) (b) sampling periods. All animals (n=6) received the two treatments in a semi-randomised order with a 2-day washout period between the LNPA+Saline (open bars) and LNPA+PCP (filled bars) condition. Data are expressed as mean ± SEM PPI (%). *p<0.05 following a Bonferroni post hoc test Fig. 4 a Mean change in prefrontal cortex NO oxidation current as compared to baseline for each 4-min sampling period corresponding to a PPI test. All animals (n=6) received the two treatment combinations in a semi-randomised order with a 2-day washout period between LNPA (5 mg/kg)+saline (open circles) and LNPA (5 mg/kg)+PCP (filled circles) condition. Data are expressed as mean ± SEM current change (pA). *p<0.05 following a Bonferroni post hoc test. b Mean change in NO oxidation current as compared to baseline for each 4-min sampling period corresponding to a PPI test. All animals (n=6) received the two treatment combinations in a semi-randomised order with a 2-day washout period between the LNPA (10 mg/kg)+saline (open circles) and LNPA (10 mg/kg)+PCP (filled circles) condition. Data are expressed as mean ± SEM current change (pA). *p<0.05 following a Bonferroni post hoc test deficit induced by PCP , and both serotonin and dopamine interact with NO signalling (Wegener et al. 2000) . However, systemic administration of PCP or its analogue MK-801 increases both the prefrontal cortex and nucleus accumbens dopamine and serotonin levels (Hernandez et al. 1988; Loscher et al. 1991) . Thus, changes in serotonin and dopamine levels are unlikely to explain the observed difference between the prefrontal cortex and the nucleus accumbens. It has been demonstrated that the NO system is regulated by NMDA receptor activity in the striatum (Park and West 2009) , whereas prefrontal cortex NO activity is more dependent on GABA receptors (Pepicelli et al. 2004) . In support of this, it was recently shown that a PCP-induced deficit in PPI could be ameliorated by the GABA B agonist baclofen in a dose that also lowered prefrontal cortex NO levels ). For the hippocampus, both GABAergic and glutamatergic modulation of NO signalling has been described (Fedele et al. 2001) . It is unclear from the literature if systemic administration of PCP affects hippocampal dopamine levels; if anything, PCP has been shown to antagonise NMDA receptor-dependent release of dopamine in a hippocampal slice preparation (Chaki et al. 1998) . Furthermore, it has been suggested that the main interaction between PCP and serotonin occurs in the dorsal and not ventral part of the hippocampus (Kusljic and van den Buuse 2004) . In summary, the broad pharmacological profile of PCP and its effect on a number of brain regions makes it difficult to draw any definite conclusions regarding the mechanism behind the observed effects on NO levels. The observed difference between the three investigated brain regions could suggest that a GABAergic and not NMDA, dopamine or serotonin receptor mechanism is primarily involved. However, PCP interacts with other neurotransmitter systems, and interactions between different receptor populations should also be considered. An additional observation from the present study is that the increase in prefrontal cortex NO was more prolonged as compared to similar experiments where animals were administered PCP in their home cage . Whether this observation is a result of the different experimental procedures, i.e. home cage versus PPI tests, or simply a result of variability between animals remains to be determined. However, recent studies show an important effect of oxidative stress in the neurotoxic effects of PCP analogues (Behrens and Sejnowski 2009) , and NO has the potential to both increase and protect against oxidative stress toxicity (Guix et al. 2005) . Furthermore, previous work has shown that both acute and subchronic administration of PCP can potentiate the behavioural response to stressful stimuli and increase stress-dependent brain c-fos immunoreactivity (Turgeon et al. 2007 ). In addition, NO may activate the HPA axis (Lopez-Figueroa et al. 1998) , and NOS inhibitors attenuate stress-induced behaviour in rats (Sevgi et al. 2006) . Thus, the present observation may reflect an interaction between PCP and a stress response converging on the NO signalling pathway.
The present data also support the involvement of neuronal NOS in the schizophrenia-related behavioural effects of PCP. The neuronal NOS inhibitor LNPA attenuated a PCP-induced deficit in PPI and dosedependently reduced a PCP-induced increase in prefrontal cortex NO levels. The time course (Klamer et al. 2005a) and neuronal NOS dependence (Klamer et al. 2004a ) of the PCP-induced deficit in PPI are in agreement with previous findings. However, the lack of correlation between NO levels and the behavioural effects of PCP stand in contrast to earlier published work ). A number of NOS inhibitors (Johansson et al. 1997; Wiley 1998) , as well as inhibition of cGMP signalling (Fejgin et al. 2008) , have been shown to attenuate a PCP-induced deficit in PPI. Furthermore, neuronal NOS knockdown mice do not show a deficit in PPI when challenged with PCP (Klamer et al. 2004c) , and thus, it may be hypothesised that NO/sGC/ cGMP signalling plays an important role in mediating some of the behavioural effects of PCP. However, the present findings demonstrate peak effects of PCP on NO levels that are temporally displaced with regards to the behavioural effects. Furthermore, a low dose of LNPA (5 mg/kg) normalised PPI without fully blocking the induction of the NO system. Thus, it would appear that increased NO levels are not directly associated with the PPI disruption induced by PCP. Interestingly, a similar temporal disassociation has been observed for increased prefrontal cortex dopamine and glutamate levels and cognitive dysfunction after PCP administration (Adams and Moghaddam 1998) . Increased glutamate levels may reflect a cortical disinhibition caused by PCP, involving GABAergic interneurons (Homayoun and Moghaddam 2007) . Importantly, within the prefrontal cortex, NOS is primarily expressed in a subpopulation of GABAergic neurons that target both pyramidal cells and other interneurons (Vruwink et al. 2001) . Thus, NO is well positioned to influence cortical activity both though synaptic and volume transmission actions. However, the lack of correlation between PCP-induced increases in prefrontal cortex NO levels and deficit in PPI remains to be reconciled with the beneficial effect of NOS inhibitors on the said deficit.
The in vivo NO levels as measured by amperometry may not accurately mirror actual synaptic NO signalling. The design of the NO sensors used in the current study, and amperometric electrodes generally employed for neurochemical analysis (∼5-300 μm in diameter), means that they monitor an average concentration of analyte in the ECF and not directly in synapses that are orders of magnitude smaller (typically <50 nM; Lowry and O'Neill 2005) . Thus, the observed effects likely reflect volume transmission of NO rather than synaptic transmission. Conceivably, synaptic NO levels are also increased but remain below the limit of detection using our method. To accurately monitor NO signalling at the synaptic level, other methods are likely needed (Sato et al. 2005) . Furthermore, the actual in vivo levels of NO have never been accurately determined, although many studies suggest that low nanomolar levels would be the likely physiological range ). Furthermore, enzymebased inactivation of NO has been demonstrated in vitro, which may limit the intercellular diffusion of NO ). Coupled with the known clearance of NO by haemoglobin, there appears to be strong constraints on the movement and half-life of NO in the cellular environment. The observable increase in NO levels following PCP administration may reflect targeted extracellular release of NO or spillover from synaptic NO signalling, although the latter seems unlikely given the time course and the magnitude of the increase . Volume transmission has been demonstrated for NO in vitro (Steinert et al. 2008) , but further studies are clearly needed to accommodate this phenomenon with models of synaptic NO signalling (Garthwaite 2010) and NO clearance in vivo (Hall and Garthwaite 2006) .
In conclusion, the present set of experiments support a previously demonstrated role of NO in the behavioural and neurochemical effects of PCP. Furthermore, this effect is brain region-specific and appears to mainly involve the neuronal isoform of NOS, but the present study also fails to demonstrate a temporal correlation between a PCP-induced disruption of PPI and an increase in prefrontal cortex NO levels. In addition, evidence of an interaction between PCP and stressful stimuli on prefrontal cortex NO levels was found. A PPI test in combination with PCP administration increased NO levels more potently than what was observed in a previous study where PCP was administered during rest. Taken together, these data suggest that the interaction between PCP and the NO system is more complex than suggested by previous work. Further studies are needed to fully elucidate the mechanism of action and functional role of NO in the behavioural and neurochemical effects of PCP.
